Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to help seniors master glucose monitors

NCT ID NCT05337826

Symptom relief Sponsor: Joslin Diabetes Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study tests a remote education program called REST, designed to help adults aged 65 and older with insulin-treated diabetes start and keep using continuous glucose monitors (CGMs). The goal is to reduce dangerous low blood sugar episodes and improve overall glucose control. Researchers will also look at what helps or hinders CGM use in this age group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Continuous Glucose Monitor (device) and remote education program (REST model)
What this could lead to
If successful, this could provide a practical, patient-centered model to help older adults with diabetes use continuous glucose monitors more effectively, reducing dangerous low blood sugar episodes.
What could go wrong
This is a relatively small study (122 participants) focused on feasibility and education, not a large-scale efficacy trial. Results may not apply to all older adults, and the program may not be widely adopted outside of research settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

122 people

The number who actually took part.

Started

Apr 2022

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Older adults age ≥65 years * T1D or T2D with duration longer than 1 year * Insulin treatment includes: ≥3 insulin injections/day or on insulin pump therapy * CGM naïve and/or CGM users (Dexcom G6) who are not meeting glycemic goals (per CGM metrics): * ≥4% hypoglycemia (sensor glucose ≤70 mg/dL) or * time in range (70-180 mg/dL) TIR ≤40 % * Willing to wear CGM Dexcom at all times while in the study * Willing to use/carry personal or loaned smart phone device to use as Dexcom receiver for continual data upload to cloud Exclusion Criteria: * Life expectancy \<1 year * End-stage renal disease (eGFR\< 30ml/min) * On acetaminophen \>4 gr/day due to interference with Dexcom G6 sensor readings * On hydroxyurea therapy due to interference with Dexcom G6 sensor readings * Impaired vision and hearing which would interfere with participation in remote video visits * Use of hybrid closed-loop systems (this may require different and additional focused education and will not be addressed in this study).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus

Contacts and locations

Locations

  • Joslin Diabetes Center

    Boston, Massachusetts, 02215, United States

  • SUNY Upstate Medical University

    Syracuse, New York, 13210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.